Doer Biologics Announces First Patient Dosed in Ib Trial of DR30206 for Platinum-Resistant Ovarian Cancer

DR30206 for injection is a Class 1 therapeutic biologic independently developed by Doer Biologics with global intellectual property rights. DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β. By blocking the PD-1/PD-L1 signaling pathway, it restores the proliferation of exhausted CD8+T cells. By specifically binding to free VEGF and TGF-β, it reduces the formation of tumor neovasculature while relieving immunosuppression, thereby achieving the purpose of killing tumors.

On June 28, 2023, Doer Biologics received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for injectable DR30206 was approved, allowing DR30206 to proceed with clinical trials for the treatment of patients with advanced solid tumors. On April 16, 2025, the first subject was dosed in the Phase Ib clinical trial for non-small cell lung cancer. On April 3, 2025, Doer Biologics received another "Clinical Trial Approval Notice" from the NMPA, approving DR30206 to conduct clinical trials in combination with standard chemotherapy for the treatment of patients with advanced or metastatic gastrointestinal tumors. On June 11, 2025, the first subject was dosed in the Phase Ib/IIa clinical study for this indication. Additionally, on November 20, 2025, DR30206 completed the first subject dosing in the single-agent expansion cohort for squamous cell carcinoma of the head and neck in the Phase Ib trial.

Completed non-clinical studies have shown that DR30206 has a clear mechanism of action and activity in inhibiting tumor growth. The ongoing Phase Ia dose-escalation and Phase Ib expansion clinical trials have both observed good safety and preliminary anti-tumor efficacy signals for DR30206.

This DR30206 Ib cohort expansion for platinum-resistant ovarian cancer plans to enroll patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (excluding mucinous and low-grade serous carcinoma) who have failed 1-3 lines of systemic anti-tumor therapy and are platinum-resistant.